Closing on Nov. 3: Investor Calendar + Company Spotlight

INVESTOR NETWORK is the go-to, one-stop site for shareholders, clients and prospective investors

Exelixis, Inc.

Exelixis, Inc.

Sector: Commercial Physical And Biological Research Region: CA, United States

: | Nasdaq: EXEL

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

Investor Calendar

Aug 1, 2018 5:00 pm | Q2 Earnings Call

May 2, 2018 5:00 pm | Q1 Earnings Call

May 2, 2018 5:00 pm | Q1 Earnings Call

Feb 26, 2018 5:00 pm | Q4 Earnings Call

Nov 1, 2017 5:00 pm | Q3 Earnings Call


Michael Morrissey, PhD, President and Chief Executive Officer
Michael M. Morrissey, Ph.D. has served as a director and as Exelixis’ President and Chief Executive Officer since July 2010. Dr. Morrissey has held positions of increasing responsibility at Exelixis since he joined the company in February 2000. From January 2007 until July 2010, he served as President of Research and Development, from January 2006 until December 2006, he served as Executive Vice President, Discovery, from January 2003 to December 2005, he served as Senior Vice President, Discovery, and from February 2000 through December 2002, he served as Vice President of Discovery Research. From 1991 to 2000, Dr. Morrissey held several positions at Berlex Biosciences, last holding the position of Vice President, Discovery Research. From 1986 to 1991, he served as a Senior Scientist and Project Team Leader in Medicinal Chemistry at CIBA-Geigy Corporation, a pharmaceutical company. He is the author of numerous scientific publications in medicinal chemistry and drug discovery and an inventor on 70 issued U.S. patents and 25 additional published U.S. patent applications. Dr. Morrissey holds a B.S. (Honors) in Chemistry from the University of Wisconsin and a Ph.D. in Chemistry from Harvard University.
Christopher J. Senner, Vice President and Chief Financial Officer
Christopher J. Senner has served as Executive Vice President and Chief Financial Officer since July 2015. Prior to joining Exelixis, Mr. Senner served as Vice President, Corporate Finance at Gilead Sciences, which he joined in March 2010. At Gilead, he was accountable for controllership and operational financial planning and analysis, including R&D, commercial operations, and tax and treasury planning. Before joining Gilead, Mr. Senner spent 18 years at Wyeth in various managerial roles of increasing responsibility, most recently serving as Vice President, Finance and Chief Financial Officer for Wyeth Pharmaceutical's U.S. Region, a position he held from July 2007 to November 2009. Before joining Wyeth, Mr. Senner worked as an accounting associate for the Research Board, an international think tank headquartered in New York. Mr. Senner obtained his B.S. in Finance from Bentley College.
P.J. Haley, Vice President, Commercial
P.J. Haley has served as Vice President and Head of Commercial at Exelixis since September 2014. P.J. joined Exelixis in 2010 as Director of Marketing, and has taken on increasing roles of responsibility within the commercial organization since. Prior to joining Exelixis, Mr. Haley held numerous roles in marketing at Genentech from 2007 to 2010 where he focused on Avastin in lung cancer, glioblastoma, and renal cell carcinoma. He worked at Amgen from 2003 to 2007 in various sales and marketing positions in both oncology and immunology. Before receiving his MBA from the University of Michigan Ross School of Business, Mr. Haley worked in investment banking and consulting. P.J. received his undergraduate degree from Duke University.
Jeffrey J. Hessekiel, J.D., Executive Vice President and General Counsel
Jeffrey J. Hessekiel, J.D., has served as Executive Vice President and General Counsel since February 2014. Prior to joining Exelixis, Mr. Hessekiel was Senior Counsel at Arnold & Porter LLP, where he advised emerging growth and public companies, primarily in the life sciences sector, on complex legal issues connected with strategic transactions, healthcare compliance programs and investigations, and regulatory matters. Previously, from 2002 to 2012, he held key legal and compliance roles at Gilead Sciences, Inc., rising to the positions of Vice President, Commercial Legal Affairs and Litigation, and then Chief Compliance and Quality Officer. Prior to joining Gilead, Mr. Hessekiel trained in the litigation and corporate practice groups at a number of Silicon Valley law firms. He also worked for several international non-governmental organizations. Mr. Hessekiel received his J.D. from George Washington University’s School of Law, and his B.A. from Duke University.
Peter Lamb, PhD, Executive Vice President, Scientific Strategy and Chief Scientific Officer
Peter Lamb, Ph.D., has served as Executive Vice President, Discovery Research and Chief Scientific Officer since September 2009. Dr. Lamb previously served in numerous other positions since joining Exelixis in October 2000, including as Senior Director, Molecular Pharmacology and Structural Biology from October 2000 until December 2003, Vice President, Discovery Pharmacology from December 2003 until January 2007 and Senior Vice President, Discovery Research and Chief Scientific Officer from January 2007 until August 2009. From June 1992 until September 2000, Dr. Lamb held positions of increasing responsibility at Ligand Pharmaceuticals, most recently serving as Director of Transcription Research. Dr. Lamb has held post-doctoral research fellowships at the Carnegie Institution, Department of Embryology, with Dr. S.L. McKnight and the University of Oxford with Dr. N.J. Proudfoot, working in the field of gene regulation. Dr. Lamb has authored numerous articles in the fields of gene expression, signal transduction and oncology, and is an author on multiple issued and pending U.S. patents. Dr. Lamb has a Ph.D. in Molecular Biology from the ICRF/University of London and a B.A. in Biochemistry from the University of Cambridge.
Gisela M. Schwab, MD, President, Product Development and Medical Affairs and Chief Medical Officer
Gisela M. Schwab, M.D., has served as President, Product Development and Medical Affairs and Chief Medical Officer since February 2016. Previously, she served as Executive Vice President and Chief Medical Officer from January 2008 until February 2016. Dr. Schwab joined Exelixis in 2006 as Senior Vice President and Chief Medical Officer. From 2002 to 2006, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. She also served as Vice President, Clinical Development, at Abgenix from 1999 to 2001. Prior to working at Abgenix, from 1992 to 1999, she held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Hematology/Oncology Therapeutic Area Team Leader. Dr. Schwab serves on the Board of Directors of Cellerant Therapeutics, Inc, and Nordic Nanovector AS. Dr. Schwab received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute and is board certified in internal medicine and hematology and oncology.

News & Analysis